Skip to content

Improving the Understanding of the Response to Vitamin D Supplementation

Improving the Understanding of the Response to Vitamin D Supplementation

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01465178
Enrollment
62
Registered
2011-11-04
Start date
2011-12-31
Completion date
2014-12-31
Last updated
2016-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D Deficiency

Keywords

hypovitaminosis D, vitamin D insufficiency, low vitamin D

Brief summary

It is the investigators hypothesis that the current method of evaluating vitamin D status, measuring circulating 25-hydroxy vitamin D is not providing the full metabolic picture, and is therefore inadequate. The investigators liken this concept to the evolution of cholesterol where initially, total cholesterol was the only measurement, and have since determined the importance of HDL, LDL and triglycerides in evaluating patient status. Similarly, the investigators feel measurement of other vitamin D components such as sulfated vitamin D, circulating vitamin D3 and 3-epi 25-hydroxy vitamin D will offer more comprehensive information about a patient's vitamin D status. It is our overarching hypothesis that a vitamin D assay panel, will enhance understanding of vitamin D status. It is our expectation that the enhanced understanding based on improved measurement capability will ultimately translate to improved definition of vitamin D status and need for supplementation on an individual level.

Detailed description

This hypothesis is supported by several observations. First, recent work finds previously unappreciated vitamin D metabolites, notably 3 epi-25(OH)D348 and sulfated 25(OH)D3, in virtually all human sera and circulating in amounts that vary widely between individuals. These compounds may be measured by current 25(OH)D assays,46, 63 and thereby confound accuracy of such measurements. Secondly, substantial but inadequately understood variability of 25(OH)D response to supplementation and UV exposure exists.15, 42-44 It is likely that currently unappreciated genetic and/or physiologic factors, e.g., differences in absorption or degradation, underpin these observations. Our panel will allow definition of these differences. Finally, the inadequacy of our current approach to classify vitamin D status (singular 25(OH)D measurement) is exemplified by the great between-individual variability in the PTH/25(OH)D relationship as noted above.8, 64 Thus, the investigators believe that exploration of a vitamin D assay panel, consisting of measurements that reflect input (cholecalciferol and ergocalciferol) and confounders to the 25(OH)D assay \[3 epi-25(OH)D and sulfated 25(OH)D\] is essential to accurately define optimal vitamin D status and to determine the ideal approach for vitamin D repletion. To begin testing this hypothesis, the Specific Aims of this research are to document the vitamin D profile response defined as change in serum concentration of: 1. 25(OH)D 2. cholecalciferol 3. 3 epi-25(OH)D 4. Sulfated 25(OH)D following four months of supplementation with 2,200 IU of daily vitamin D3 in postmenopausal women. Our primary outcome variable is the effect of supplementation on serum 25(OH)D3; secondary outcomes are change in cholecalciferol, 3 epi-25(OH)D3 and sulfated 25(OH)D3.

Interventions

DIETARY_SUPPLEMENTcholecalciferol

2000 IU cholecalciferol gelcaps by mouth daily

DIETARY_SUPPLEMENTPlacebo

matching placebo

Sponsors

Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
50 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy, community-dwelling ambulatory postmenopausal White, non-Hispanic women * Able and willing to sign informed consent * Baseline serum 25(OH)D concentration of 10-29 ng/mL * Willing to not alter the amount of their baseline vitamin D supplementation during the course of this study * Willing to use sunscreen (SPF ≥15) when sun exposure of \> 15 minutes is expected

Exclusion criteria

* Presence of any measurable circulating 25(OH)D2 on screening measurement * Current hypercalcemia (serum calcium \> 10.5 mg/dl) or untreated primary hyperparathyroidism * History of nephrolithiasis * Known risk factors for hypercalcemia, e.g., malignancy, tuberculosis, sarcoidosis * History of any form of cancer within the past five years with the exception of adequately treated squamous cell or basal cell skin carcinoma * Renal failure; defined as a calculated creatinine clearance (using the Cockroft-Gault approach) of ≤ 35 ml/minute * Severe end-organ disease, e.g., cardiovascular, hepatic, hematologic, pulmonary, etc., which might limit the ability to complete this study * Known metabolic bone disease, e.g., Paget's disease, osteomalacia * Treatment with any drug known to interfere with vitamin D metabolism, e.g., phenytoin, phenobarbital * Treatment with high dose vitamin D (≥ 50,000 IU weekly) or any active metabolites of vitamin D, e.g., calcitriol, within six months of screening * Use of tanning beds or salons or unwillingness to utilize sunscreen during periods of sun exposure of 15 minutes or longer * Planned trips/vacations likely to be associated with substantial amounts of sun exposure during the course of the study

Design outcomes

Primary

MeasureTime frameDescription
Change in Serum 25-hydroxy Vitamin D3Baseline, 1 and 4 months post supplementationOur primary outcome variable is the effect of supplementation on change in serum 25(OH)D3;

Secondary

MeasureTime frameDescription
Change in Parameters of the Vitamin D Assay PanelBaseline, 1 and 4 months post supplementationSecondary outcomes are change in cholecalciferol, 24,25(OH)D3 and free 25(OH)D3.

Countries

United States

Participant flow

Recruitment details

Enrollment started December 2011 and ended December 2014. Subjects were enrolled from the community and research was conducted at the University of Wisconsin Osteoporosis Clinical Research Program.

Pre-assignment details

No adverse events were reported between screening and randomization. All screened volunteers that were not enrolled in the study were deemed ineligible based on 25(OH)vitamin D being outside the study entry criterion.

Participants by arm

ArmCount
2000 IU Vitamin D3
Cholecalciferol 2,000 IU capsules cholecalciferol: 2000 IU cholecalciferol gelcaps by mouth daily
31
Placebo
Non-matching placebo, gelatin filled capsules Placebo: matching placebo
31
Total62

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject10

Baseline characteristics

Characteristic2000 IU Vitamin D3TotalPlacebo
Age, Continuous69.7 years
STANDARD_DEVIATION 9.7
67.8 years
STANDARD_DEVIATION 9.1
65.9 years
STANDARD_DEVIATION 8.2
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
31 Participants62 Participants31 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
31 Participants62 Participants31 Participants
Region of Enrollment
United States
31 participants62 participants31 participants
Sex: Female, Male
Female
31 Participants62 Participants31 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 314 / 31
serious
Total, serious adverse events
0 / 310 / 31

Outcome results

Primary

Change in Serum 25-hydroxy Vitamin D3

Our primary outcome variable is the effect of supplementation on change in serum 25(OH)D3;

Time frame: Baseline, 1 and 4 months post supplementation

ArmMeasureGroupValue (MEAN)Dispersion
2000 IU Vitamin D3Change in Serum 25-hydroxy Vitamin D3One Month6.0 ng/mlStandard Deviation 4.1
2000 IU Vitamin D3Change in Serum 25-hydroxy Vitamin D3Four Month10.4 ng/mlStandard Deviation 5.8
PlaceboChange in Serum 25-hydroxy Vitamin D3One Month-0.8 ng/mlStandard Deviation 4.3
PlaceboChange in Serum 25-hydroxy Vitamin D3Four Month0.3 ng/mlStandard Deviation 4.1
Secondary

Change in Parameters of the Vitamin D Assay Panel

Secondary outcomes are change in cholecalciferol, 24,25(OH)D3 and free 25(OH)D3.

Time frame: Baseline, 1 and 4 months post supplementation

Population: Postmenopausal Caucasian women with 25(OH)D \< 10 \> 30 ng/ml

ArmMeasureGroupValue (MEAN)Dispersion
2000 IU Vitamin D3Change in Parameters of the Vitamin D Assay PanelCholecalciferol Month 46.7 ng/mlStandard Deviation 5.7
2000 IU Vitamin D3Change in Parameters of the Vitamin D Assay Panel24,25(OH)D3 Month 41.2 ng/mlStandard Deviation 0.91
2000 IU Vitamin D3Change in Parameters of the Vitamin D Assay PanelCholecalciferol Month 16.7 ng/mlStandard Deviation 4.3
2000 IU Vitamin D3Change in Parameters of the Vitamin D Assay Panel24,25(OH)D3 Month 10.3 ng/mlStandard Deviation 0.08
2000 IU Vitamin D3Change in Parameters of the Vitamin D Assay Panelfree 25(OH)D3 Month 42.4 ng/mlStandard Deviation 1.9
2000 IU Vitamin D3Change in Parameters of the Vitamin D Assay Panelfree 25(OH)D3 Month 11.3 ng/mlStandard Deviation 1.3
PlaceboChange in Parameters of the Vitamin D Assay Panelfree 25(OH)D3 Month 4-0.1 ng/mlStandard Deviation 1.3
PlaceboChange in Parameters of the Vitamin D Assay PanelCholecalciferol Month 1-0.6 ng/mlStandard Deviation 1.3
PlaceboChange in Parameters of the Vitamin D Assay PanelCholecalciferol Month 4-0.20 ng/mlStandard Deviation 2.12
PlaceboChange in Parameters of the Vitamin D Assay Panel24,25(OH)D3 Month 1-0.2 ng/mlStandard Deviation 0.5
PlaceboChange in Parameters of the Vitamin D Assay Panel24,25(OH)D3 Month 4-0.1 ng/mlStandard Deviation 0.56
PlaceboChange in Parameters of the Vitamin D Assay Panelfree 25(OH)D3 Month 1-0.2 ng/mlStandard Deviation 1

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026